Actelion Pharmaceuticals US, Inc., today announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis®, for the treatment of New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). This increased strength formulation delivers the same dose of Ventavis in half the volume, which is expected to reduce inhalation time and …
Posted over 2 years ago
Nanocrystals make dentures shine
Research team develops advanced live-imaging approach (w/ video)
Tunable nano-suspensions for light harvesting
Tagging tumors with gold: Scientists use gold nanorods to flag brain tumors
Laser Hardware/Control Software Engineer I (209) - Hanscom AFB, MA
Postdoctoral Position - La Jolla, CA
Research Engineer position in Super-resolution microscopy - Castelldefels (Barcelona), Spain
Physicist/Physical Chemist/Research Engineer (We Sponsor Clearances) - Lexington, MA
AACR 103rd Annual Meeting 2012
Conference on Lasers and Electro-Optics and the...
